Business
Novo Nordisk Faces Shareholder Lawsuits
Shareholders are suing Novo Nordisk over its handling of CagriSema's weight-loss drug, citing misleading market information after disappointing clinical trial results.
Coverage timeline — 1 article
CNBC
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.
2026-07-29 13:11 UTC